A decision on PBS listing for Trikafta (elexacaftor/tezacaftor/ivacaftor) for treatment of cystic fibrosis has been deferred for a second time by the Pharmaceutical Benefits Advisory Committee (PBAC). At a May intracycle meeting the PBAC again deferred on making a recommendation based on revised submission from manufacturer Vertex for Trikafta to be listed for the treatment ...
Trikafta’s second PBAC deferral disappoints CF advocates
By Michael Woodhead
22 Jun 2021